Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Vanda Pharmaceuticals (VNDA) over the last 17 years, with Q3 2025 value amounting to -$0.38.

  • Vanda Pharmaceuticals' EPS (Basic) fell 32222.22% to -$0.38 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.43, marking a year-over-year decrease of 39310.34%. This contributed to the annual value of -$0.33 for FY2024, which is 91256.65% down from last year.
  • Vanda Pharmaceuticals' EPS (Basic) amounted to -$0.38 in Q3 2025, which was down 32222.22% from -$0.46 recorded in Q2 2025.
  • In the past 5 years, Vanda Pharmaceuticals' EPS (Basic) ranged from a high of $0.17 in Q2 2021 and a low of -$0.5 during Q1 2025
  • For the 5-year period, Vanda Pharmaceuticals' EPS (Basic) averaged around -$0.05, with its median value being $0.0 (2023).
  • Per our database at Business Quant, Vanda Pharmaceuticals' EPS (Basic) soared by 150000.0% in 2021 and then crashed by 297595.15% in 2024.
  • Vanda Pharmaceuticals' EPS (Basic) (Quarter) stood at $0.13 in 2021, then decreased by 7.69% to $0.12 in 2022, then plummeted by 141.67% to -$0.05 in 2023, then plummeted by 68.95% to -$0.08 in 2024, then plummeted by 349.85% to -$0.38 in 2025.
  • Its last three reported values are -$0.38 in Q3 2025, -$0.46 for Q2 2025, and -$0.5 during Q1 2025.